InMode (INMD) Scheduled to Post Earnings on Thursday

InMode (NASDAQ:INMD) will issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.40 per share for the quarter. InMode has set its FY24 guidance at $2.53-2.57 EPS.Investors that wish to register for the company’s conference call can do so using this link.

InMode (NASDAQ:INMD) last announced its quarterly earnings results on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. InMode had a return on equity of 29.80% and a net margin of 40.22%. The business’s revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.69 earnings per share. On average, analysts expect InMode to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

InMode Stock Up 0.5 %

NASDAQ:INMD opened at $17.23 on Tuesday. InMode has a 12-month low of $16.82 and a 12-month high of $48.25. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of 7.49 and a beta of 2.16. The stock’s 50 day moving average price is $20.21 and its two-hundred day moving average price is $21.45.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on INMD shares. UBS Group increased their price target on InMode from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, February 14th. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Tuesday, April 9th. Finally, Barclays cut their target price on shares of InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, April 12th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, InMode currently has a consensus rating of “Hold” and a consensus price target of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.